Lancet[journal] 检索结果

21. Bundled interventions to prevent acute kidney injury: finding the value in supportive care.

作者: Edward D Siew.
来源: Lancet. 2025年

22. Michael Manns.

作者: Andrew Green.
来源: Lancet. 2025年406卷10517期2316页

23. Department of Error.

来源: Lancet. 2025年406卷10517期2324页

24. Department of Error.

来源: Lancet. 2025年406卷10517期2324页

25. Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study - Authors' reply.

作者: Mohamed Abdel-Fattah.;Karen Ward.;Simon Dixon.;Christopher Chapple.;Graeme MacLennan.;John Norrie.
来源: Lancet. 2025年406卷10517期2322-2324页

26. Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study.

作者: Thomas M Kessler.;Lucas M Bachmann.;Cornelia Betschart.
来源: Lancet. 2025年406卷10517期2322页

27. Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study.

作者: Maurizio Serati.;Tufan Tarcan.;Benoit Peyronnet.;Eskinder Solomon.;Enrico Finazzi-Agro.
来源: Lancet. 2025年406卷10517期2321-2322页

28. Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study.

作者: Manuela Tutolo.;Enrico Ammirati.;Francesco Montorsi.
来源: Lancet. 2025年406卷10517期2320-2321页

29. Aligning SPIRIT and SAGER guidelines for equity in clinical trials - Authors' reply.

作者: An-Wen Chan.;Isabelle Boutron.;Sally Hopewell.;David Moher.;Kenneth F Schulz.;Asbjørn Hróbjartsson.
来源: Lancet. 2025年406卷10517期2320页

30. Aligning SPIRIT and SAGER guidelines for equity in clinical trials.

作者: Shirin Heidari.;Thomas F Babor.;Joan Marsh.;Bahar Mehmani.;Roli Mathur.
来源: Lancet. 2025年406卷10517期2319-2320页

31. WHO global report on hypertension 2025.

作者: Jeremy Farrar.;Tom Frieden.
来源: Lancet. 2025年406卷10517期2318-2319页

32. Georges C Benjamin: resolute defender of public health in the USA.

作者: Faith McLellan.
来源: Lancet. 2025年406卷10517期2313页

33. Offline: A reservoir of illusions (part 1).

作者: Richard Horton.
来源: Lancet. 2025年406卷10517期2308页

34. Translational social medicine for global health: introducing Cases in Global Social Medicine.

作者: Seth M Holmes.;Mayssa Rekhis.;Scott D Stonington.;Mirko Pasquini.;Luke Messac.;Eugene Raikhel.;Junko Kitanaka.;Valéria Macedo.;Paola Sesia.;Carlos Piñones Rivera.;Tinashe Goronga.;Salmaan Keshavjee.;Benson A Mulemi.;Margareta Matache.;Michael Marmot.
来源: Lancet. 2025年406卷10517期2306-2307页

35. The dawn of immunotherapy in mismatch repair proficient colorectal cancer.

作者: Gertjan Rasschaert.;Sabine Tejpar.
来源: Lancet. 2025年406卷10517期2302-2304页

36. Europe cannot get sidetracked from basic health-care needs.

作者: The Lancet.
来源: Lancet. 2025年406卷10517期2295页

37. Exploring CAR NK-cell therapy for refractory lupus.

作者: Alberta Hoi.
来源: Lancet. 2025年

38. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.

作者: Jie Gao.;Mengtao Li.;Ming Sun.;Yiyi Yu.;Ruina Kong.;Xia Xu.;Suxuan Liu.;Qian Chen.;Xiaofang Li.;Yang Wu.;Enshun Xu.;Jianmin Yang.;Dongbao Zhao.
来源: Lancet. 2025年

Lately, autologous CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent efficacy in treatment of autoimmune diseases, but with great safety concerns, such as infections. In this study, we aimed to evaluate the safety, tolerability, and efficacy of allogeneic CD19 CAR natural killer (NK)-cell therapy in patients with relapsed or refractory systemic lupus erythematosus (SLE).

39. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

作者: Mazen Noureddin.;Stephen A Harrison.;Rohit Loomba.;Naim Alkhouri.;Naga Chalasani.;Muhammad Y Sheikh.;Shaheen Tomah.;Julio A Gutierrez.;Silvia Urbina.;John J Suschak.;Randy Brown.;Ozioma Odili.;Jay Yang.;Stephine Keeton.;Guy Neff.;Edward Mena.;M Scot Roberts.;Sarah K Browne.;M Scott Harris.
来源: Lancet. 2025年

GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment.

40. Personalised prevention therapy in type 1 diabetes.

作者: Bart O Roep.
来源: Lancet. 2025年

结果排序

文献格式

出版时间

出版类型

出版语言